Hypomagnesemia is defined as serum magnesium <1.7 mg/dL (<0.7 mmol/L), present in 3–10% of the general population but in >65% of ICU patients. [1] It is frequently underdiagnosed because serum magnesium is not routinely measured and <1% of total body magnesium resides in plasma. [1] The following figure from the NEJM review on magnesium disorders illustrates magnesium homeostasis, clinical manifestations, and therapeutic approaches:
1. History
- Characterize symptoms: muscle cramps, weakness, fatigue, lethargy, tremor, paresthesias, palpitations [1-2]
- Timing: acute onset (post-surgical, medication change, alcohol binge) vs. chronic/insidious (PPI use, poor intake, chronic diarrhea)
- GI history: diarrhea frequency/chronicity, steatorrhea, short bowel syndrome, bariatric surgery, NG suctioning, vomiting [2]
- Dietary intake: green leafy vegetables, nuts, whole grains, meats — assess for malnutrition or restrictive diets [3]
- Medication review: PPIs, diuretics (loop/thiazide), aminoglycosides, cisplatin, calcineurin inhibitors, EGFR inhibitors, amphotericin B [1-2]
- Alcohol use: quantity, duration, last drink, withdrawal symptoms [3]
- Important negatives: seizure history, syncope, palpitations, chest pain, prior electrolyte abnormalities
2. Alarm Features
- Seizures or tetany (carpopedal spasm, Trousseau/Chvostek signs) — indicates severe hypomagnesemia (<1.2 mg/dL) [1]
- Cardiac arrhythmias: torsades de pointes, ventricular tachycardia, atrial fibrillation [1][4]
- Refractory hypokalemia or hypocalcemia not responding to replacement — classic clue to underlying magnesium depletion [1-2]
- Hemodynamic instability, altered mental status, respiratory depression
- Concurrent digoxin use — hypomagnesemia increases digoxin toxicity [2]
3. Medications
Causative agents (high-yield list): [1-2][5]
- PPIs — ~20% incidence with long-term use; dose-dependent; reduced intestinal absorption [1][6]
- Loop diuretics (furosemide, bumetanide) and thiazide diuretics — renal magnesium wasting
- Aminoglycosides, amphotericin B, cisplatin, pentamidine, foscarnet — direct tubular toxicity
- Calcineurin inhibitors (tacrolimus, cyclosporine) — 20–40% incidence [1]
- EGFR inhibitors (cetuximab, erlotinib) — 20–40% incidence [1]
- Metformin — associated with lower magnesium levels [7]
Treatment medications
- Oral: magnesium oxide (least absorbed), magnesium citrate, glycinate, gluconate (better absorbed organic salts) [1]
- IV: magnesium sulfate — indicated for severe/symptomatic cases [8-9]
- Adjuvant: amiloride — reduces renal magnesium wasting; useful in refractory cases [1]
- SGLT2 inhibitors may raise serum magnesium, especially in diabetic patients [1][10]
Cautions
- Oral magnesium commonly causes diarrhea, which can worsen depletion [1]
- Reduce IV magnesium dose in renal insufficiency (max 20 g/48 hours) [8]
4. Diet
- Magnesium-rich foods: dark leafy greens (spinach, kale), nuts (almonds, cashews), seeds, legumes, whole grains, dark chocolate, avocados [3]
- Alcohol cessation is critical — ethanol impairs both GI absorption and renal reabsorption [1][3]
- Oral inulin (prebiotic fiber) may improve magnesium absorption in PPI-induced hypomagnesemia by modifying gut microbiome and luminal pH [1][6]
- Adequate hydration; avoid excessive caffeine (mild magnesiuric effect)
- Long-term: dietary counseling for patients on chronic diuretics or PPIs
5. Review of Systems
- Neuro: tremor, paresthesias, seizures, confusion, lethargy, hyperreflexia
- Cardiac: palpitations, syncope, chest pain
- MSK: muscle cramps, weakness, fasciculations
- GI: nausea, vomiting, diarrhea, anorexia (both symptom and cause)
- Psych: irritability, depression, personality changes
- Endocrine: polyuria/polydipsia (diabetes screening), symptoms of hypocalcemia (perioral numbness)
6. Collateral History and Family History
- Alcohol use: collateral from family/friends regarding true intake
- Medication adherence: confirm PPI, diuretic, or immunosuppressant use and duration
- Family history: Gitelman syndrome, Bartter syndrome, familial hypomagnesemia with secondary hypocalcemia (HSH) — pathogenic variants identified in ~80% of familial cases [1]
- Nutritional status: caregiver input on dietary intake, especially in elderly or institutionalized patients
- Social context: homelessness, food insecurity, eating disorders
7. Risk Factors
- Alcohol use disorder — present in ~30% of these patients [3]
- Type 2 diabetes mellitus — prevalence 10–30% due to insulin resistance and renal wasting [1]
- Hospitalization, especially ICU admission (>65%) [1]
- Chronic PPI use [1][6]
- Chronic diuretic therapy [2]
- Malabsorptive states: celiac disease, IBD, short bowel syndrome, chronic diarrhea, bariatric surgery [2]
- Elderly patients with polypharmacy — number of medications inversely correlates with magnesium levels [7]
- Organ transplant recipients on calcineurin inhibitors [1]
- Cancer patients on cisplatin or EGFR inhibitors [1]
8. Differential Diagnosis
When evaluating symptoms that may be caused by hypomagnesemia, consider:
- Hypocalcemia (primary) — similar neuromuscular symptoms; check PTH, vitamin D [1][3]
- Hypokalemia (primary) — often coexists; refractory hypokalemia is a hallmark clue to concurrent magnesium depletion [1]
- Hypophosphatemia — weakness, rhabdomyolysis; frequently coexists in alcoholism [3]
- Thyrotoxicosis — tremor, palpitations, weakness
- Primary hyperaldosteronism — hypokalemia, metabolic alkalosis, hypomagnesemia [1]
- Gitelman syndrome — hypomagnesemia + hypokalemia + metabolic alkalosis + hypocalciuria [1]
- Bartter syndrome — similar electrolyte pattern but with hypercalciuria [2]
Key distinguishing pearl: Refractory hypokalemia or hypocalcemia that does not correct with standard replacement should always prompt checking and correcting magnesium first. [1-2]
9. Past Medical History
- Prior episodes of electrolyte abnormalities
- Diabetes mellitus (type 2 especially)
- Chronic kidney disease or prior AKI
- GI surgery (bowel resection, bariatric surgery, ostomy)
- Chronic diarrheal illness (IBD, celiac, chronic pancreatitis)
- Organ transplantation
- Malignancy and chemotherapy history
- Cardiac history (arrhythmias, heart failure — diuretic use)
10. Physical Exam
Vital signs
Focused exam
- Trousseau sign: carpal spasm with BP cuff inflation (shared with hypocalcemia) [3]
- Chvostek sign: facial muscle twitch with tapping of facial nerve
- Hyperreflexia, tremor, fasciculations, nystagmus
- Muscle weakness (proximal > distal)
- Signs of chronic alcohol use: spider angiomata, palmar erythema, hepatomegaly
- Signs of malnutrition: temporal wasting, poor dentition, peripheral edema
11. Lab Studies
Initial labs
- Serum magnesium (normal 1.7–2.4 mg/dL) — a low level usually indicates significant total body depletion [1]
- BMP: potassium, calcium, phosphorus, creatinine, glucose
- Ionized calcium — more accurate than total calcium
- Serum albumin — hypoalbuminemia can affect magnesium measurement [1]
Etiologic workup (if cause unclear)
- 24-hour urine magnesium or fractional excretion of magnesium (FEMg):
- FEMg >2% in the setting of hypomagnesemia → renal wasting [1-2]
- FEMg <2% → GI losses or poor intake
- Magnesium loading test — for suspected occult depletion with normal serum levels [1-2]
Concurrent electrolyte abnormalities to expect
Monitoring
- Serial magnesium levels during replacement
- Potassium and calcium levels — often correct once magnesium is repleted [1][3]
12. Imaging
- Not routinely indicated for hypomagnesemia itself
- Chest X-ray / CT: if clinical concern for aspiration (seizure), pneumonia, or underlying malignancy
- Echocardiography: if new arrhythmia or heart failure suspected
- Abdominal imaging: if evaluating for GI cause (short bowel, pancreatitis, malabsorption)
13. Special Tests
- Fractional excretion of magnesium (FEMg): key test to distinguish renal vs. GI losses [1]
- Formula: FEMg = (Urine Mg × Serum Cr) / (0.7 × Serum Mg × Urine Cr) × 100
- The 0.7 correction factor accounts for protein-bound magnesium
- Parenteral magnesium loading test: infuse magnesium and measure 24-hour urine retention; >50% retention suggests total body depletion [1-2]
- Point-of-care ionized magnesium: available on some blood gas analyzers; clinical utility remains unclear [1]
- Genetic testing: consider in young patients with unexplained, persistent hypomagnesemia and family history (Gitelman, TRPM6 mutations) [1]
14. ECG
Indications: obtain ECG in all symptomatic patients and those with Mg <1.2 mg/dL [11]
ECG findings in hypomagnesemia: [12-14]
- Prolonged QTc interval — most consistent finding
- Prolonged Tp-e interval and increased Tp-e/QTc ratio — markers of ventricular repolarization heterogeneity and arrhythmia risk [12]
- Widened P wave (atrial depolarization dispersion) [13]
- Global T-wave inversions — reported in isolated hypomagnesemia [14]
- ST depression, flattened T waves
- Torsades de pointes — classically associated; IV magnesium is first-line treatment even with normal magnesium levels [4]
- Increased PVC frequency, especially in heart failure patients on diuretics [11]
Pearl: Magnesium is an independent predictor of QTc prolongation (β = −20.3 ms per unit increase in Mg). [12] Continuous telemetry monitoring is recommended for moderate-to-severe electrolyte imbalances. [11]
15. Assessment
Severity stratification
- Mild: Mg 1.2–1.7 mg/dL — often asymptomatic or nonspecific symptoms (fatigue, cramps) [1]
- Severe: Mg <1.2 mg/dL — neuromuscular irritability, arrhythmias, seizures [1]
Key clinical pearls
- Serum magnesium is a poor proxy for total body stores — a low level indicates significant depletion, but a normal level does not exclude deficiency [1]
- Always check magnesium when encountering refractory hypokalemia or hypocalcemia [1]
- Hypomagnesemia is associated with increased all-cause and cardiovascular mortality [1]
- In alcoholic patients, magnesium may drop further after admission due to intracellular shifts from glucose/insulin administration, correction of acidosis, and catecholamine surges during withdrawal [3]
16. Treatment Plan
Acute / Severe (Mg <1.2 mg/dL, symptomatic, arrhythmias, seizures):
- IV magnesium sulfate 1–2 g (8–16 mEq) in 50–100 mL D5W or NS over 15–60 minutes, followed by 4–8 g over 24 hours via continuous infusion [8-9]
- For torsades de pointes: IV magnesium sulfate 1–2 g bolus over 5–15 minutes [4]
- For severe deficiency: up to 5 g (40 mEq) in 1 L D5W over 3 hours [8]
- Monitor deep tendon reflexes, respiratory rate, and urine output during IV infusion [8]
- Maximum 30–40 g/day; in renal insufficiency, max 20 g/48 hours [8]
Mild to Moderate (asymptomatic or mild symptoms)
- Oral magnesium: 240–1000 mg elemental magnesium daily in divided doses
- Prefer organic salts (citrate, glycinate, gluconate, lactate) over inorganic (oxide) for better absorption [1]
- Titrate to bowel tolerance (diarrhea is dose-limiting)
Adjunctive / Refractory
- Amiloride 5–10 mg daily — reduces renal magnesium wasting; particularly useful in diuretic-induced or Gitelman syndrome [1]
- SGLT2 inhibitors — may increase serum magnesium in diabetic patients [1][10]
- Oral inulin — for PPI-induced hypomagnesemia [1][6]
- Discontinue or reduce offending medications when possible (switch PPI to H2 blocker, adjust diuretic) [1]
Always co-replace potassium and calcium — these will often remain refractory until magnesium is corrected. [1][3]
17. Disposition
Admit / Observe
- Symptomatic severe hypomagnesemia (seizures, tetany, arrhythmias)
- Mg <1.0 mg/dL
- Concurrent significant hypokalemia or hypocalcemia
- ECG abnormalities (prolonged QTc, torsades de pointes, ventricular arrhythmias)
- Active alcohol withdrawal
- Hemodynamic instability
Discharge criteria
- Mild, asymptomatic hypomagnesemia with identifiable and correctable cause
- Stable vital signs, normal ECG, no arrhythmia
- Able to tolerate oral replacement
- Reliable follow-up arranged
Specialist consultation triggers
- Nephrology: unexplained renal magnesium wasting, suspected Gitelman/Bartter syndrome, refractory hypomagnesemia
- Cardiology: new arrhythmias, torsades de pointes
- GI: suspected malabsorptive etiology
18. Follow Up / Return Precautions
Follow-up timing
- Recheck serum magnesium within 1–2 days after IV repletion (rapid renal excretion of infused magnesium)
- Outpatient: recheck in 1–2 weeks after starting oral supplementation
- Continue supplementation for at least 3–5 days after normalization to replete intracellular stores [15]
Return precautions — instruct patients to return for
- Muscle spasms, twitching, or cramping that worsens
- Palpitations, irregular heartbeat, chest pain, or syncope
- Seizures, confusion, or altered mental status
- Numbness/tingling around the mouth or in the hands/feet
Patient counseling
- Emphasize dietary magnesium intake (leafy greens, nuts, seeds)
- Alcohol cessation counseling if applicable
- Discuss PPI de-escalation with primary care if on long-term PPI
- Expected recovery: symptoms typically resolve within hours of IV repletion; oral repletion of total body stores may take days to weeks [1][15]
References
1. Magnesium Disorders. — Touyz RM, de Baaij JHF, Hoenderop JGJ. The New England Journal of Medicine. 2024.
2. Magnesium Deficiency: Pathophysiologic and Clinical Overview. — al-Ghamdi SM, Cameron EC, Sutton RA. American Journal of Kidney Diseases : The Official Journal of the National Kidney Foundation. 1994.
3. Electrolyte Disturbances in Patients with Chronic Alcohol-Use Disorder. — Palmer BF, Clegg DJ. The New England Journal of Medicine. 2017.
4. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). — European Heart Rhythm Association, Heart Rhythm Society, Zipes DP, et al. Journal of the American College of Cardiology. 2006.
5. Drug-Induced Alterations in Mg2+ Homoeostasis. — Lameris AL, Monnens LA, Bindels RJ, Hoenderop JG. Clinical Science. 2012.
6. Mechanisms of Proton Pump Inhibitor-Induced Hypomagnesemia. — Gommers LMM, Hoenderop JGJ, de Baaij JHF. Acta Physiologica. 2022.
7. Drug Use Is Associated With Lower Plasma Magnesium Levels in Geriatric Outpatients; Possible Clinical Relevance. — van Orten-Luiten ACB, Janse A, Verspoor E, Brouwer-Brolsma EM, Witkamp RF. Clinical Nutrition. 2019.
8. FDA Drug Label. — Updated date: 2021-12-13. Food and Drug Administration.
9. FDA Drug Label. — Updated date: 2026-04-23. Food and Drug Administration.
10. Magnesium Biology. — Kröse JL, de Baaij JHF. Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association. 2024.
11. Update to Practice Standards for Electrocardiographic Monitoring in Hospital Settings: A Scientific Statement From the American Heart Association. — Sandau KE, Funk M, Auerbach A, et al. Circulation. 2017.
12. Serum Magnesium and Ventricular Repolarization Heterogeneity: A Case-Control Study Based on Electrocardiographic Parameters. — Aslan R, Özkan Hİ, Özel F, Özmen M, Ardahanlı İ. Se Biological Trace Element Research. 2026.
13. The ECG Characteristics of Patients With Isolated Hypomagnesemia. — Yang Y, Chen C, Duan P, et al. Frontiers in Physiology. 2021.
14. Global T-Wave Inversions With Isolated Hypomagnesemia. — Tsai TF, Browning AC, Rutledge J. The Journal of Emergency Medicine. 2013.
15. Acquired Disorders of Hypomagnesemia. — Rosner MH, Ha N, Palmer BF, Perazella MA. Mayo Clinic Proceedings. 2023.